Novel Long-Lesion DES Sails Through Pivotal Trial

(MedPage Today) -- PHOENIX -- The novel, next-generation Xience drug-eluting stent (DES) with a 48-mm length met the performance bar with a particularly low restenosis rate, the SPIRIT 48 trial showed. The Xience Skypoint 48 stent had a target...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news